58 studies found for:    "Carcinoid syndrome"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Withdrawn Study of Panitumumab in the Treatment of Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: Panitumumab
2 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start);   Drug: Mid-low dose LX1606 - Day 15 (start);   Drug: Mid-high dose LX1606 - Day 29 (start);   Drug: High dose LX1606 - Day 43 (start);   Drug: 4-Week LX1606 Open Label Dose Extension;   Drug: 72-Week LX1606 Open Label Dose Extension
3 Terminated Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Condition: Malignant Carcinoid Syndrome
Interventions: Drug: lanreotide Autogel (somatostatin analogue);   Drug: Sandostatin long acting release (LAR) Depot (somatostatin analogue)
4 Completed Effects of Serotonin Excess on Bone in Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention:
5 Completed Telotristat Etiprate for Carcinoid Syndrome Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo
6 Terminated Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: Octreotide
7 Completed
Has Results
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Condition: Carcinoid Syndrome
Interventions: Drug: Somatuline Depot (lanreotide);   Drug: placebo
8 Terminated
Has Results
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: BIM 23A760
9 Completed TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo tablets
10 Completed A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Condition: Neuroendocrine Tumour (NET) With Carcinoid Syndrome
Intervention:
11 Active, not recruiting Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condition: Carcinoid Syndrome
Intervention: Drug: Telotristat etiprate tablets (250 mg)
12 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 Part 1;   Drug: Mid-Low Dose LX1606 Part 1;   Drug: Mid-High Dose LX1606 Part 1;   Drug: High Dose LX1606 Part 1;   Drug: Part 2 LX1606 Expanded Cohort;   Drug: Placebo;   Drug: LX1606 Open Label Dose Extension;   Drug: LX1606 Open Label Extension 2;   Drug: LX1606 Open Label Extension 3
13 Completed An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
Condition: Carcinoid Syndrome
Intervention: Drug: 500 mg [14C]-LX1606
14 Completed
Has Results
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Conditions: Carcinoid Tumor;   Malignant Carcinoid Syndrome
Interventions: Drug: Octreotide;   Drug: Placebo;   Drug: Everolimus
15 Terminated
Has Results
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Octreotide LAR
16 Completed Azilect + Antidepressant Chart Review
Condition: Serotonin Syndrome
Interventions: Drug: Group R+AD Rasagiline + Antidepressant;   Drug: Group R Rasagiline;   Drug: Group AD Anti-PD + Antidepressant
17 Not yet recruiting Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: regorafenib;   Other: laboratory biomarker analysis
18 Suspended Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Atypical Carcinoid Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Midgut Carcinoid Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Regional Digestive System Neuroendocrine Tumor G1
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment
19 Completed Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Adult Solid Neoplasm;   Lung Carcinoid Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Renal Cell Carcinoma;   Recurrent Uterine Corpus Sarcoma;   Stage III Renal Cell Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Uterine Sarcoma;   Stage IV Renal Cell Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Temsirolimus;   Biological: Trebananib
20 Completed Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: Cixutumumab;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Octreotide Acetate;   Other: Pharmacological Study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years